See more : GrainCorp Limited (GNC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Guardant Health, Inc. (GH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardant Health, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Skylight Health Group Inc. (SLHPF) Income Statement Analysis – Financial Results
- Compass Digital Acquisition Corp. (CDAQW) Income Statement Analysis – Financial Results
- Banca Popolare di Sondrio S.p.A (BPSO.MI) Income Statement Analysis – Financial Results
- Charger Metals NL (CHR.AX) Income Statement Analysis – Financial Results
- Careplus Group Berhad (0163.KL) Income Statement Analysis – Financial Results
Guardant Health, Inc. (GH)
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 563.95M | 449.54M | 373.65M | 286.73M | 214.38M | 90.64M | 49.84M | 25.25M |
| Cost of Revenue | 227.05M | 156.33M | 122.91M | 92.54M | 70.72M | 43.21M | 31.62M | 22.12M |
| Gross Profit | 336.90M | 293.21M | 250.74M | 194.20M | 143.66M | 47.43M | 18.22M | 3.13M |
| Gross Profit Ratio | 59.74% | 65.23% | 67.11% | 67.73% | 67.01% | 52.33% | 36.56% | 12.38% |
| Research & Development | 367.19M | 373.81M | 263.22M | 149.86M | 86.29M | 50.71M | 25.56M | 10.86M |
| General & Administrative | 155.80M | 163.96M | 206.64M | 192.77M | 61.40M | 36.19M | 36.78M | 9.92M |
| Selling & Marketing | 295.23M | 299.83M | 191.88M | 106.51M | 78.34M | 53.47M | 32.50M | 26.19M |
| SG&A | 451.03M | 463.78M | 398.52M | 299.28M | 139.73M | 89.66M | 69.27M | 36.11M |
| Other Expenses | 83.40M | -112.56M | 25.18M | 3.64M | 88.00K | 4.70M | -1.06M | -1.00K |
| Operating Expenses | 901.62M | 837.59M | 661.74M | 449.15M | 226.03M | 140.37M | 94.84M | 46.97M |
| Cost & Expenses | 1.13B | 993.92M | 784.65M | 541.68M | 296.75M | 183.58M | 126.45M | 69.10M |
| Interest Income | 35.37M | 6.07M | 3.93M | 10.17M | 13.74M | 5.27M | 2.23M | 733.00K |
| Interest Expense | 2.58M | 2.58M | 2.58M | 4.77M | 1.18M | 1.25M | 2.70M | 3.02M |
| Depreciation & Amortization | 42.88M | 35.96M | 22.27M | 16.07M | 13.61M | 7.14M | 5.21M | 3.69M |
| EBITDA | -433.31M | -614.91M | -359.62M | -225.07M | -54.93M | -75.84M | -75.31M | -39.42M |
| EBITDA Ratio | -76.83% | -144.79% | -102.21% | -84.10% | -31.97% | -91.54% | -140.91% | -156.13% |
| Operating Income | -564.73M | -544.38M | -411.00M | -254.95M | -82.37M | -92.94M | -76.61M | -43.85M |
| Operating Income Ratio | -100.14% | -121.10% | -110.00% | -88.92% | -38.42% | -102.54% | -153.71% | -173.66% |
| Total Other Income/Expenses | 85.96M | -109.07M | 26.53M | 9.05M | 12.65M | 8.72M | -6.60M | -2.29M |
| Income Before Tax | -478.76M | -653.45M | -384.47M | -245.90M | -69.72M | -84.23M | -83.21M | -46.13M |
| Income Before Tax Ratio | -84.90% | -145.36% | -102.89% | -85.76% | -32.52% | -92.92% | -166.96% | -182.71% |
| Income Tax Expense | 685.00K | 1.14M | 300.00K | 379.00K | -1.87M | 38.00K | 7.00K | 6.00K |
| Net Income | -479.45M | -654.59M | -384.77M | -246.28M | -67.85M | -85.06M | -83.22M | -46.14M |
| Net Income Ratio | -85.02% | -145.61% | -102.98% | -85.89% | -31.65% | -93.85% | -166.97% | -182.74% |
| EPS | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| EPS Diluted | -4.28 | -6.41 | -3.80 | -2.53 | -0.75 | -2.80 | -1.18 | -0.65 |
| Weighted Avg Shares Out | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
| Weighted Avg Shares Out (Dil) | 111.99M | 102.18M | 101.31M | 97.50M | 90.60M | 30.40M | 70.72M | 70.72M |
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Guardant Health to Participate in Upcoming Investor Conferences
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
FDA Advisory Panel Review of Guardant Health's Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Source: https://incomestatements.info
Category: Stock Reports